首页> 外文OA文献 >Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

【2h】

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

机译：Cemiplimab的阶段I扩增队列，一种人PD-1单克隆抗体，与放疗（RT），环磷酰胺和GM-CSF组合，患者（PTS），具有复发性或转移头和颈部鳞状细胞癌（R / M HNSCC ）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
H.M. Babiker; I. Brana; D. Mahadevan; T.K. Owonikoko; E. Calvo; D. Rischin; V. Moreno; K.P. Papadopoulos; M. Crittenden; S. Formenti; J. Giralt; P. Garrido; A. Hervás Morón; K.K. Mohan; M.G. Fury; I. Lowy; E. Stankevich; M. Feng; J. Li; M. Mathias;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head [J] . Baselga J, Trigo JM, Bourhis J, Journal of Clinical Oncology . 2005,第24期

机译：抗表皮生长因子受体单克隆抗体西妥昔单抗联合铂类化学疗法在铂难治性转移性和/或复发性头颅癌患者中的II期多中心研究
2. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort [J] . Chow Laura Q. M., Haddad Robert, Gupta Shilpa, Journal of Clinical Oncology . 2016,第32期

机译：Pembrolizumab在未选择生物标志物的复发性和/或转移性头颈部鳞状细胞癌患者中的抗肿瘤活性：Ib期KEYNOTE-012扩展队列的结果
3. 97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) [J] . J.Bourhis, F.Rivera, R.Mesia, European Journal of Cancer Supplements . 2003,第5期

机译：97西妥昔单抗（C225）与顺铂或卡铂和5-氟尿嘧啶（5-FU）联合用于头颈部复发和/或转移性鳞状细胞癌（R＆M SCCHN）患者（pts）的I期研究
4. Intelligent analysis of methylation data in Head and Neck Squamous Cell Carcinoma (HNSCC) interactomes [C] . Saad Zaheer, Sabaoon Zeb, Faisal F. Khan International Conference on Artificial Intelligence . 2021

机译：头颈鳞状细胞癌（HNSCC）椎间囊组致甲基化数据智能分析
5. Non-invasive in vivo assessment of tumor hypoxia using functional magnetic resonance (fMR) imaging during therapy in human head and neck squamous cell carcinoma (HNSCC) xenografts: Implications for assessing therapeutic efficacy. [D] . Bhattacharya, Arup. 2005

机译：在人头颈部鳞状细胞癌（HNSCC）异种移植物治疗期间，使用功能性磁共振（fMR）成像对肿瘤缺氧进行非侵入性体内评估：评估治疗功效的意义。
6. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort [O] . Laura Q.M. Chow, Robert Haddad, Shilpa Gupta, -1

机译：Pembrolizumab在未选择生物标志物的复发性和/或转移性头颈部鳞状细胞癌患者中的抗肿瘤活性：Ib期KEYNOTE-012扩展队列的结果
7. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony‐Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [O] . Hani Babiker, Irene Brana, Daruka Mahadevan, 2021

机译：Cemimplimab，放射治疗，环磷酰胺和粒细胞巨噬细胞癌症患者的患者的I相试验，患者复发或转移性头部和颈部鳞状细胞癌的刺激因子

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

著录项

相似文献

相关主题

期刊订阅